NASDAQ:SIGA - Nasdaq - US8269171067 - Common Stock - Currency: USD
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American pharmaceutical […]
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced...
Siga Technologies Inc. (SIGA) closed at $5.48 in the latest trading session, marking a -1.26% move from the prior day.
General Keane brings significant expertise in national security and biodefense preparedness...
Increased Product Sales to $133 Million in 2024Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in...
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $5.43, indicating a -1.63% shift from the previous trading day.
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that...
Siga Technologies Inc. (SIGA) reachead $6.51 at the closing of the latest trading day, reflecting a +0.39% change compared to its last close.
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.25, representing a +1.96% change from its previous close.
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $5.93, marking a -1.82% move from the previous day.
SIGA Technologies’ (NASDAQ:SIGA) antiviral drug tecovirimat, when used without other treatments, did not reduce the time for clade ...
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced...
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno...
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy...
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in...
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in...
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...
/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...